Prilenia Plans to Submit Marketing Authorization Application in the EU for Pridopidine in Huntington’s Disease

Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael Hayden, CEO of Prilenia “Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families. These Read more…

en_USEnglish